Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Daniel R, Kapusta"'
Autor:
Jake E. Doiron, Zhen Li, Xiaoman Yu, Kyle B. LaPenna, Heather Quiriarte, Timothy D. Allerton, Kashyap Koul, Andrew Malek, Sanjiv J. Shah, Thomas E. Sharp, Traci T. Goodchild, Daniel R. Kapusta, David J. Lefer
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 4 (2024)
Background The renal sympathetic nervous system modulates systemic blood pressure, cardiac performance, and renal function. Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejec
Externí odkaz:
https://doaj.org/article/377b6dd424934dd9a1525c1d2e497cee
Autor:
Jake Doiron, Zhen Li, Huijing Xia, Kyle B. Lapenna, Timothy D. Allerton, Daniel R. Kapusta, David J. Lefer
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 108-108 (2023)
OBJECTIVES/GOALS: SGLT2i therapy is currently a cornerstone in heart failure with preserved ejection fraction (HFpEF) therapy. Similarly, H2S has been shown to be beneficial in preclinical models of heart failure. With this in mind, we sought to inve
Externí odkaz:
https://doaj.org/article/7c8d629aa0cc47b5be07f44d739a356d
Autor:
Zhuoying Wang, Ian Denys, Feng Chen, Lijie Cai, Xuecui Wang, Daniel R. Kapusta, Yongliang Lv, Juan Gao
Publikováno v:
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-4 (2019)
Abstract Background Timolol Maleate is a non-selective beta-adrenergic blocker that is commonly used to treat open-angle glaucoma. Despite its topical administration, ophthalmic timolol enters systemic circulation and produces a systemic beta-adrener
Externí odkaz:
https://doaj.org/article/94d088f4055f454ea163a98e403cf1c6
Publikováno v:
Hypertension
Nalfurafine is a G-protein–biased KOR (kappa opioid receptor) agonist that produces analgesia and lacks central nervous system adverse effects. Here, we examined the cardiovascular and renal responses to intravenous and oral nalfurafine alone and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::583a30651455d09e91b9ddad6bd04ef6
https://pubmed.ncbi.nlm.nih.gov/34852633
https://pubmed.ncbi.nlm.nih.gov/34852633
Publikováno v:
Journal of Clinical and Translational Science, Vol 3, Pp 19-19 (2019)
OBJECTIVES/SPECIFIC AIMS: We have reported that radiofrequency renal denervation (RF-RDN) in SHR at 20-weeks of age, decreased blood pressure (BP) and fibrosis in kidney cortex and medulla when rats were sacrificed at 6 months. However, whether RF-RD
Externí odkaz:
https://doaj.org/article/f5334cd6a0254c9ca32f4adadd03039a
Publikováno v:
Pharmacological research. 185
Difelikefalin is a peripherally restricted kappa opioid receptor (KOR) agonist that was recently approved by the FDA to treat pruritis in dialysis patients. Here, we investigated the cardiovascular and renal responses to difelikefalin, and using the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b5918de20130ee99dff95b15fdbc1b7
https://pubmed.ncbi.nlm.nih.gov/36202183
https://pubmed.ncbi.nlm.nih.gov/36202183
Autor:
Sarah Mahne, Jonathan S. Williams, Crissey L. Pascale, Daniel R. Kapusta, Richard D Wainford, Casey Y. Carmichael, Douglas L. Rosene, Jill T. Kuwabara, J. Thomas Cunningham, Jesse D. Moreira
Publikováno v:
Hypertension. 75:1002-1011
We have previously reported that in salt-resistant rat phenotypes brain, Gαi 2 (guanine nucleotide–binding protein alpha inhibiting activity polypeptide 2) proteins are required to maintain blood pressure and sodium balance. However, the impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a62913321ed4c1114b0ba410ea46ad9
https://doi.org/10.1161/hypertensionaha.119.13777
https://doi.org/10.1161/hypertensionaha.119.13777
Publikováno v:
Br J Pharmacol
Background and purpose Partial agonists of the nociceptin opioid peptide (NOP) receptor have potential therapeutic use as antihypertensive and water diuretic (aquaretic) agents. However, to date, peptide NOP receptor ligands have failed to progress i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::936ae472e8ad33e7d125e917e5f4fccf
https://europepmc.org/articles/PMC8716424/
https://europepmc.org/articles/PMC8716424/
Publikováno v:
Journal of Clinical and Translational Science, Vol 2, Pp 25-25 (2018)
OBJECTIVES/SPECIFIC AIMS: The goal of this study was to investigate whether RF-RDN attenuates renal fibrosis and inflammation in SHR with established hypertension. METHODS/STUDY POPULATION: Twenty-two-week-old SHR received bilateral RF-RDN or Sham-RD
Externí odkaz:
https://doaj.org/article/358153a79b2b44b7a55ba98219a39871
Autor:
Chandramohan Ramasamy, Kailash N. Pandey, Prerna Kumar, Ramachandran Samivel, Daniel R. Kapusta, Hanqing Zhao, Kandasamy Neelamegam, Christian Nguyen, Venkateswara R Gogulamudi, Huijing Xia
Publikováno v:
The FASEB Journal. 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fb66c432b9d4740389ec4857c5b799c
https://doi.org/10.1096/fasebj.2021.35.s1.03773
https://doi.org/10.1096/fasebj.2021.35.s1.03773